CXCL8 and neoplasm: Additional studies are clearly needed to more fully understand the impact of the chemokine-secretory response on clinical outcomes in patients receiving drugs that interfere with glutamine metabolism, as well as the potential benefits of combining these agents with antagonists of IL-8 and other tumour-derived chemokines.